The "Europe Biopsy Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe Biopsy Device market is expected to reach US$ 1.13 billion by 2033 from US$ 672.6 million in 2024, with a CAGR of 6.01% from 2025 to 2033.
The increasing need for sophisticated, affordable, and adaptable solutions that improve operational efficiency is propelling the market. The market expansion in Europe is also being supported by the growing demand for minimally invasive procedures, adherence to stringent regulations, technological developments in imaging and automation, and a growing focus on early cancer detection and preventive healthcare, which guarantees quicker and more precise diagnoses.
The increasing incidence of cancer, technical developments, and a growing focus on early diagnosis and minimally invasive procedures are all contributing to the continuous expansion of the biopsy instrument market in Europe. Breast, prostate, and lung cancers are among the many cancers that can be detected by biopsy equipment, which are used to remove tissue samples for diagnostic examination. The need for precise diagnostic tools has increased as cancer rates in Europe continue to grow, primarily as a result of aging populations and lifestyle factors. Furthermore, advancements in biopsy methods including image-guided biopsy, fine-needle aspiration, and core needle biopsy are improving the accuracy and efficacy of diagnoses. The market for biopsy devices has grown as a result of these advancements.
Further expansion is being fueled by the growing use of automated and robotically assisted biopsy technologies. Both patients and healthcare professionals find these technologies more appealing since they give more accuracy, shorter operation times, and less patient discomfort. Additional drivers of market expansion include the expanding number of cutting-edge healthcare facilities and encouraging government initiatives to provide access to healthcare.
Europe has a well-established healthcare system and a high degree of medical knowledge, which fosters the adoption of innovative biopsy technology. Driven by technological innovation and growing healthcare requirements, the biopsy device business in Europe is expected to continue its upward trajectory as the demand for diagnostic procedures increases and healthcare practitioners look for more precise and efficient ways.
The region's high cancer case prevalence is probably going to contribute to the market's expansion. For example, according to Globocan 2020, there were a projected 531,000 new instances of breast cancer in Europe in 2020; by 2040, that figure is predicted to rise to 568,000. Additionally, the same source claims that of all the cancer forms, breast cancer is the most prevalent.
Growth Drivers for the Europe Biopsy Device Market
Raising Knowledge of Early Diagnosis
A major cultural change toward proactive healthcare is being driven by public awareness campaigns and healthcare programs throughout Europe that highlight the significance of early cancer identification. Early diagnosis enables therapy to start earlier, which frequently improves patient survival rates and quality of life. The frequency of biopsies performed to confirm or rule out illnesses has also increased as more people are seeking medical examinations earlier. Because biopsy procedures are essential for making quick and accurate diagnoses, the emphasis on preventive healthcare and early intervention is driving up demand for them. Access to modern diagnostic services is also being facilitated by increased government funding and support for public health initiatives.
Furthermore, the demand for accurate, dependable, and minimally invasive biopsy technologies is being reinforced throughout Europe by the increased awareness among patients and medical professionals of the long-term advantages of early detection. According to the 2024 article, the European Commission showcased its efforts during the European Week Against Cancer (May 25-31), emphasizing the EU's Beating Cancer Plan, which focuses on prevention, early identification, and treatment. Addressing inequities, sophisticated cancer imaging, and the #GetScreenedEU campaign are important initiatives. The initiative, which has €4 billion behind it, encourages innovation and better patient care.
Increasing Focus on Accuracy and Efficiency in Medical Procedures
The expansion is being driven by the growing emphasis on optimizing clinical operational efficiency and simplifying healthcare processes. The growing need for sophisticated, adaptable solutions that improve workflow effectiveness is consistent with the larger trend of healthcare optimization. The introduction of integrated biopsy systems and kits, which provide streamlined methods for diagnostic and interventional treatments, is being driven by the need for time-saving, cost-effective instruments. Furthermore, the development and approval of novel biopsy technologies are being promoted by adherence to strict regulatory criteria. This increases the gadgets' legitimacy and uptake by guaranteeing that they fulfill strict safety and performance requirements.
The development of automated systems and advanced imaging technologies, among other advancements in biopsy equipment, is significantly driving market expansion. Because of their accuracy, ease of use, and ability to produce findings quickly, instruments including robotic-assisted biopsy systems, liquid biopsy techniques, and ultrasound-guided biopsy needles are growing in popularity in Europe.
By enabling more precise tissue sample collection, these technological advancements help medical professionals reduce problems, speed up recovery, and increase diagnostic accuracy. By improving targeting precision and enabling real-time decision-making during treatments, artificial intelligence (AI) in robotics and imaging is improving the biopsy process. Additionally, the industry is moving toward innovations that improve patient outcomes and lessen discomfort due to the growing desire for minimally invasive procedures.
Challenges in the Europe Biopsy Device Market
Inconsistent Healthcare Access
Even while Europe's healthcare system is typically strong, access to sophisticated diagnostic instruments, such as biopsy devices, varies greatly, especially in rural areas and in nations with weaker healthcare budgets. Early diagnostic services may not be as readily available in less affluent areas since hospitals and clinics may find it difficult to purchase state-of-the-art technology.
Furthermore, the expense of running and maintaining sophisticated biopsy equipment may prevent their broad use in public health systems. It is difficult to deliver consistent, high-quality healthcare in every location as a result of this unequal resource distribution. Delays in diagnosis and treatment consequently affect underprivileged areas, which restricts the market potential for biopsy equipment in these areas and slows the growth of the sector as a whole.
Competition and Price Sensitivity
With multiple manufacturers offering a broad range of equipment, from sophisticated robotic-assisted systems to conventional manual tools, the European biopsy device industry is quite competitive. In addition to spurring innovation, this rivalry puts pressure on prices, especially in public healthcare systems with limited funding. Price sensitivity is a major issue since hospitals and clinics frequently choose less expensive options over high-end goods, particularly in areas with different economies.
Even though cutting-edge biopsy technologies increase efficiency and accuracy, their high upfront costs and continuing maintenance requirements may prevent widespread adoption. Therefore, price sensitivity may restrict the adoption of expensive equipment, impacting the market's potential for growth and making it more difficult for some healthcare settings to access state-of-the-art diagnostic instruments.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 90 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value (USD) in 2024 | $0.67 Billion |
| Forecasted Market Value (USD) by 2033 | $1.13 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Europe |
Company Analysis: Overview, Recent Developments, Revenue Analysis
- Becton, Dickinson and Company
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories
- Exact Sciences (Genomic Health)
- Biocept
- Roche Diagnostics
- Myriad Genetics Inc.
- Qiagen
- NeoGenomics Laboratories
- Quest Diagnostics Inc.
Key Topics Covered:
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Europe Biopsy Device Market
6. Market Share
6.1 By Products
6.2 By Imaging Technology
6.3 By County
6.4 By End User
7. Product
7.1 Needle Based Biopsy Devices
7.2 Biopsy Forceps
7.3 Localization Wire
7.4 Others Products
8. Imaging Technology
8.1 CT Scan
8.2 Stereotactic Guided
8.3 Ultrasound Guided
8.4 Mri Guided
8.5 Others
9. Country
9.1 United Kingdom
9.2 France
9.3 Germany
9.4 Italy
9.5 Spain
9.6 Russia
9.7 Rest of Europe
10. End User
10.1 Hospital and Clinics
10.2 Diagnostics Laboratories
10.3 Other
11. Porter's Five Forces Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Competition
11.4 Threat of New Entrants
11.5 Threat of Substitutes
12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threats
13. Key Players Analysis
For more information about this report visit https://www.researchandmarkets.com/r/vcwlsn
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250410122456/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
